Skip to content
BillHelp
Menu
YOUR BILLHELP GUIDE

IVIG Denied by Insurance

What can I do if insurance denies IVIG?

A plan can deny intravenous immune globulin, called IVIG, because an approval was missing, because its policy says another treatment must be tried first, because of the diagnosis, or because of where the infusion was given. Medicare Part B has a specific home benefit for IVIG when you have a primary immune deficiency disease and the other conditions in that benefit are met. A different national policy covers IVIG only for certain blistering diseases, and only short term. This page explains the denial and the appeal. It does not promise that the infusion will be covered.

Get help with my bill →
General U.S. guidance. Your plan documents and denial notice explain the process that applies to your case. Medicare, Medicaid, and other programs may use different rules. This is not medical or legal advice, and no result is guaranteed.

What should I read on an IVIG denial?

Read the denial for the product name, the diagnosis, the date, the place it was given, and the reason. A missing approval, a requirement to try another treatment first, a limit on the diagnosis, and a limit on the site of care are different disputes. HealthCare.gov says preauthorization is a decision that a service is medically necessary, and that it is not a promise of payment. If the notice says approval was missing, see a prior authorization denial. If it says the infusion is not medically necessary, see a medical necessity denial.

Ask the plan whether it processed the infusion as a medical benefit or as a pharmacy benefit. The appeal form can differ. Immune globulin products have their own FDA labels, and labeled uses differ by product. Use the product name on the denial. This page does not restate those labels. A denial of an iron infusion is a different drug. See an iron infusion denial. A specialty-drug restriction is in a specialty medication denial.

References: HealthCare.gov: Preauthorization · HealthCare.gov: Internal appeals

When does Medicare cover IVIG at home?

These Medicare points were checked on CMS Transmittal 12352, issued November 8, 2023, and on CMS MLN3191598, February 2026. Medicare Benefit Policy Manual, Chapter 15, Section 50.6, says the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 provides coverage of IVIG for the treatment of primary immune deficiency diseases in the home. The manual says the Act defines intravenous immune globulin as an approved pooled plasma derivative for the treatment of primary immune deficiency disease. It is covered under this benefit when the patient has a diagnosed primary immune deficiency disease, it is administered in the home, and the physician determines that administration in the home is medically appropriate. The manual says it is not necessary for the derivative to be administered through durable medical equipment. The manual names diagnosis codes for this benefit. Use the code on your denial together with the manual, rather than a shortened list.

Section 4134 of the Consolidated Appropriations Act, 2023, made payment for items and services related to home administration permanent for infusions furnished on or after January 1, 2024. The manual says that payment is a separate bundled payment to a durable medical equipment supplier for all items and services furnished in the home during a calendar day. CMS's February 2026 fact sheet says that payment is separate from the payment for the IVIG drug. It says a pump is not covered under that items-and-services payment. CMS's February 2026 fact sheet says a patient's home is a place of residence used as a home, including an institution, and that a hospital, a critical access hospital, or a skilled nursing facility is not an eligible institutional home setting. The same fact sheet says patients may receive immune globulin intravenously or under the skin, and then states the Part B home benefit for IVIG when the four conditions above are met. Do not treat a subcutaneous product as this IVIG benefit unless the denial says it is. This page does not restate payment amounts.

A Medicare Advantage plan follows traditional Medicare coverage rules for this benefit. 42 CFR 422.101(b) says the organization must follow CMS national coverage determinations, general coverage and benefit conditions in traditional Medicare, and written local coverage decisions for the area. The plan's appeal is in how to appeal a Medicare Advantage denial. Home health aide visits are a different benefit. See a home health coverage denial.

References: CMS Transmittal 12352 (November 8, 2023): Medicare Benefit Policy Manual, Chapter 15, Section 50.6, home IVIG · CMS MLN3191598 (February 2026): Intravenous immune globulin items and services · 42 CFR 422.101: Medicare Advantage basic benefits, including traditional Medicare coverage criteria

What does NCD 250.3 cover?

National Coverage Determination 250.3 is a different rule. Effective October 1, 2002, it covers IVIG for the treatment of biopsy-proven pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane pemphigoid (also called cicatricial pemphigoid), and epidermolysis bullosa acquisita, for patients who have failed conventional therapy, patients in whom conventional therapy is contraindicated, or patients with rapidly progressive disease in whom, in the NCD's words, a clinical response could not be affected quickly enough using conventional agents. In that last group, the NCD says IVIG is given along with conventional treatment and used only until the conventional therapy could take effect. The NCD says contractors define what counts as failure, what counts as a contraindication, and what counts as short-term therapy. It says IVIG for these diseases must be used only for short-term therapy and not as maintenance therapy. This page does not state a number of weeks.

A diagnosis that is not primary immune deficiency under the home benefit, and is not one of those five blistering diseases, is not decided by those two national policies. Ask whether a local coverage determination applies, and ask for the policy the denial used. Do not treat another plan's list of diagnoses as Medicare's rule.

References: NCD 250.3: Intravenous immune globulin for the treatment of autoimmune mucocutaneous blistering diseases

What if the infusion was in an office or a hospital?

A private plan's written policy may cover the infusion in a hospital outpatient department, an infusion center, a physician's office, or at home, and it may refuse a site. Ask for that policy. This page does not state a national site-of-care rule for a private plan.

Outside the home primary-immune-deficiency benefit, Medicare Part B has setting rules for a drug that is not usually self-administered. 42 CFR 410.26 covers those drugs incident to a physician's service in a noninstitutional setting when the conditions in that section are met. 42 CFR 410.27 is the hospital outpatient rule, including drugs and biologicals which are not usually self-administered. An infusion at home is not, by these two sections, the same as the home primary-immune-deficiency benefit in Chapter 15, Section 50.6. Ask which section, if any, the denial applied. 42 CFR 423.100 says a drug for which payment is available under Part A or Part B, as prescribed and dispensed or administered, is not a Part D drug. 42 CFR 423.578(e) says a Part D exception cannot be used for a drug that is not a Part D drug.

A private plan's policy may also require another treatment before IVIG. That requirement is the plan's policy unless the notice cites a Medicare rule. 42 CFR 422.136 limits Medicare Advantage step therapy for a Part B drug to new administrations, with a lookback of at least 365 days, and the required drug has to be one the plan covers. Ask for the policy. Do not ask anyone to record a trial that did not happen. The general step-therapy appeal is in a step therapy denial.

References: 42 CFR 410.26: Services and supplies incident to a physician's service, including drugs not usually self-administered · 42 CFR 410.27: Outpatient hospital services incident to a physician's service, including drugs not usually self-administered · 42 CFR 423.100: Part D drug definition · 42 CFR 423.578: Medicare Part D exceptions process · 42 CFR 422.136: Medicare Advantage step therapy for Part B drugs · CMS Transmittal 12352 (November 8, 2023): Medicare Benefit Policy Manual, Chapter 15, Section 50.6, home IVIG

How do I appeal an IVIG denial?

Use the notice. Ask the prescriber for a letter of medical necessity and the records the policy asks for, including the diagnosis. The letter should answer the reason on the denial.

For a private plan, 29 CFR 2560.503-1 gives a group health plan at least 180 days after you receive the denial to appeal, and 45 CFR 147.136 applies that standard to non-grandfathered group and individual coverage. HealthCare.gov says to file within 180 days, and to request an external review in writing within 4 months when the dispute is a medical judgment. If the notice gives a later date, use the notice. For a private-sector workplace health plan, the Department of Labor says an urgent appeal must be decided as soon as your medical needs require, and no later than 72 hours after the plan receives the appeal. A scheduled infusion is not automatically that urgent appeal. Ask the prescriber, and use the process on the notice. The steps are in how to appeal a health insurance denial and how to request an external review.

For Original Medicare, 42 CFR 405.942 says a redetermination must be filed within 120 calendar days after you receive the notice. Receipt is presumed five calendar days after the date on the notice unless there is evidence otherwise. The steps are in how to appeal an Original Medicare denial. For a Medicare Advantage plan, when the plan grants a request to expedite a Part B drug decision, 42 CFR 422.572 says the decision is due as expeditiously as your health requires and no later than 24 hours after the plan receives the request. A clinician's call does not move the deadline unless the notice says it does.

References: 29 CFR 2560.503-1: Claims procedure, including the 180-day appeal period · 45 CFR 147.136: Internal claims, appeals, and external review · HealthCare.gov: Internal appeals · HealthCare.gov: External review · U.S. Department of Labor: Filing a claim for your health benefits · 42 CFR 405.942: Original Medicare redetermination filing deadline · Medicare.gov: Appeals in Original Medicare · 42 CFR 422.572: Timeframes for expedited Medicare Advantage organization determinations

What this page cannot promise

This is general information, not medical or legal advice. The home Medicare benefit is for primary immune deficiency disease, in the home, when the physician finds home administration medically appropriate. NCD 250.3 is limited to five blistering diseases and to short-term therapy. Another diagnosis depends on the policy the denial names. A Part D exception does not cover a Part B drug. An appeal can leave the denial in place. Nothing on this page promises that IVIG will be covered or that a bill will be canceled.

Sources and further help

These sources provide general guidance. For a deadline or requirement that applies to you, follow your plan’s notice or the appropriate program’s current instructions.

Insurer websites may ask you to select your state or sign in. If a page will not open, use the member services number on your insurance card and ask for the current appeal instructions for your plan.

Report a broken link or suggest a correction.

← Explore all 141 guides